Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).
E. Raymond
Consultant or Advisory Role - Pfizer
Honoraria - Bayer; Pfizer
Research Funding - Bayer; Pfizer
P. Niccoli
No relevant relationships to disclose
J. Raoul
No relevant relationships to disclose
Y. Bang
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
I. Borbath
No relevant relationships to disclose
C. Lombard-Bohas
No relevant relationships to disclose
J. W. Valle
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
P. Metrakos
No relevant relationships to disclose
D. Smith
No relevant relationships to disclose
A. Vinik
Research Funding - Pfizer
Other Remuneration - Pfizer
J. Chen
No relevant relationships to disclose
D. Hoersch
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Research Funding - Covidien; ITG; Novartis
D. E. Castellano
No relevant relationships to disclose
H. F. Kennecke
Honoraria - Novartis; Pfizer
Research Funding - Pfizer
Expert Testimony - Pfizer (U)
J. Picus
Honoraria - Pfizer
Research Funding - Pfizer
G. Van Hazel
Consultant or Advisory Role - Pfizer
D. Lu
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
R. C. Chao
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
S. Patyna
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
E. Van Cutsem
Research Funding - Pfizer